Considering that EGFR inhibitors activate autophagy in bladder cancer cells, we proceeded to determine whether concurrent inhibition of autophagy activities can enhance the anti-cancer effects of EGFR inhibitors. The gene discussed is EGFR; the disease is urinary bladder carcinoma.